Erlotinib in paediatric ependymoma previously treated with etoposide

• Research type

  Research Study

• Full title

  Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Paediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205

• IRAS ID

  69578

• Contact name

  Stergios Zacharoulis

• Sponsor organisation

  OSI Pharmaceuticals Inc

• Eudract number

  2010-023478-38

• Clinicaltrials.gov Identifier

  NCT01247922

• Research summary

  Ependymoma is the third most common central nervous system tumour type in children. There are few options for treatment of these tumours and the role of chemotherapy remains unclear. The primary objective of this study is to find out what the most common side effects of erlotinib are when given to patients with recurrent or refractory paediatric ependymoma. Patients randomised to etoposide in the 774-205 protocol who discontinue due to toxicty or lack of etoposide efficacy, may be eligible to receive erlotinib in this follow-on study. Up to 20 patients will be entered into this study from centres in the UK, United States of America and Canada.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  11/H0720/9

• Date of REC Opinion

  26 Apr 2011

• REC opinion

  Further Information Favourable Opinion